IPG-1094 is under clinical development by Immunophage Biotech and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IPG-1094’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IPG-1094 overview

IPG-1094 is under development for the treatment of systemic lupus erythematosus, psoriasis, multiple sclerosis, multiple myeloma, colon cancer, and advanced solid tumors including brain glioma, triple-negative breast cancer, head and neck cancer, small-cell lung cancer and non-small cell lung cancer. It is administered through oral route. The drug candidates act by targeting macrophage migration inhibitory factor (MIF).

Immunophage Biotech overview

Immunophage Biotech (Immunophage) is an innovative drug research and development company. Immunophage is headquartered in Shanghai, China.

For a complete picture of IPG-1094’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.